AI Verdict
PCRX has stronger fundamentals based on our AI analysis.
PCRX vs PCB Fundamental Comparison
| Metric | PCRX | PCB |
|---|---|---|
| Revenue | $726.4M | $2.9M |
| Net Income | $7.0M | $37.5M |
| Net Margin | 1.0% | 1,291.9% |
| ROE | 1.0% | 9.6% |
| ROA | 0.6% | 1.1% |
| Current Ratio | 4.54x | N/A |
| Debt/Equity | 0.54x | 0.00x |
| EPS | $0.16 | $2.58 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCRX vs PCB: Frequently Asked Questions
Is PCRX or PCB a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PCRX has stronger fundamentals. PCRX is rated HOLD (65% confidence) while PCB is rated SELL (65% confidence). This is not investment advice.
How does PCRX compare to PCB fundamentally?
Pacira BioSciences, Inc. has ROE of 1.0% vs PCB BANCORP's 9.6%. Net margins are 1.0% vs 1,291.9% respectively.
Which stock pays higher dividends, PCRX or PCB?
PCRX has a dividend yield of N/A or no dividend while PCB has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCRX or PCB for long term?
For long-term investing, consider that PCRX has HOLD rating with 65% confidence, while PCB has SELL rating with 65% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCRX vs PCB?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCRX vs PCB, the AI consensus favors PCRX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.